drugset / Trial / NCT00588146
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
Phase 2
Terminated
10 enrolled
Mayo Clinic
Augusta University · collabSchering-Plough · collabUnity Health Toronto · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT). Funding Source - FDA Office of Orphan Products Development (OOPD)
Timeline
- Start
- 2007-01
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1 ug/kg | Subcutaneous |